NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 30 November 2011 This modelling study used data from the ACTIVE-W and ACTIVE-A studies to allow a comparison of dual therapy with aspirin plus clopidogrel versus aspirin alone in […]
Category Archives: Cardiovascular disease
NPC Archive Item: Dronedarone▼ increases the risk of heart failure, stroke and death compared to placebo in people with permanent AF
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 28 November 2011 The PALLAS study found that, in patients with permanent atrial fibrillation (AF) at high risk of vascular events, dronedarone▼ more than doubled the risk of the […]
NPC Archive Item: NICE publishes guidance on ticagrelor▼ for acute coronary syndromes
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 11 November 2011 NICE recommends ticagrelor (Brilique▼) in combination with low-dose aspirin for up to 12 months as a treatment option for adults with acute coronary syndromes (ACS), i.e. […]
NPC Archive Item: Diagnostic ambulatory blood pressure monitoring reduces misdiagnosis and costs
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 31 October 2011 The cost-effectiveness modelling study underpinning the recommendations on blood pressure measurement in the updated NICE hypertension guidance, has recently been published. It concludes that, when used […]
NPC Archive Item: New evidence supports more rigorous measurement of blood pressure for the diagnosis of hypertension
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 11 October 2011 A systematic review has found that clinic and home blood pressure (BP) measurement have insufficient accuracy to be used as a single diagnostic test and may […]
NPC Archive Item: EMA recommends restricting the use of dronedarone▼
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 29 September 2011 Following a review of its benefit-risk balance, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended that dronedarone▼ should only […]
NPC Archive Item: What is the optimal duration of anticoagulant therapy following VTE?
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 25th August 2011 A pooled analysis of data from seven randomised controlled trials (RCTs) suggests that three months of anticoagulant treatment is generally sufficient following a venous thromboembolism (VTE) […]
NPC Archive Item: New NICE guidance on management of stable angina
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. The NICE Centre for Clinical Practice is an NHS Evidence accredited provider 19 August 2011 New NICE guidance on the management of stable angina (clinical guideline [CG] 126) has […]
NPC Archive Item: A2RAs: no substantially increased risk of MI, but ACE inhibitors still first line
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 28 June 2011 A large meta-analysis provides evidence that angiotensin-II receptor antagonists (A2RAs) do not substantially increase the risk of MI, all-cause or CV mortality, or angina, as was […]
NPC Archive Item: Olmesartan reduces disease oriented outcomes but may have potential cardiovascular safety concerns
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 28th March 2011 The ROADMAP trial found olmesartan delayed the onset of microalbuminuria in patients with type 2 diabetes and normoalbuminuria. While this disease-oriented outcome (DOO) suggested a potential benefit […]